sitagliptin / metformin hydrochloride sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
catapresan 150 mikrog tabletti
glenwood gmbh pharmazeutische erzeugnisse - clonidine hydrochloride - tabletti - 150 mikrog - klonidiini
verpamil 40 mg tabletti, kalvopäällysteinen
orion corporation - verapamili hydrochloridum - tabletti, kalvopäällysteinen - 40 mg - verapamiili
verpamil 80 mg tabletti, kalvopäällysteinen
orion corporation - verapamil hydrochloride - tabletti, kalvopäällysteinen - 80 mg - verapamiili
verpamil 120 mg tabletti, kalvopäällysteinen
orion corporation - verapamil hydrochloride - tabletti, kalvopäällysteinen - 120 mg - verapamiili
verpamil 200 mg depottabletti
orion corporation - verapamil hydrochloride - depottabletti - 200 mg - verapamiili
revia 50 mg tabletti, kalvopäällysteinen
paranova oy - naltrexoni hydrochloridum - tabletti, kalvopäällysteinen - 50 mg - naltreksoni
ondansetron bluefish 4 mg tabletti, kalvopäällysteinen
bluefish pharmaceuticals ab bluefish pharmaceuticals ab - ondansetroni hydrochloridum dihydricum - tabletti, kalvopäällysteinen - 4 mg - ondansetroni
ondansetron bluefish 8 mg tabletti, kalvopäällysteinen
bluefish pharmaceuticals ab bluefish pharmaceuticals ab - ondansetroni hydrochloridum dihydricum - tabletti, kalvopäällysteinen - 8 mg - ondansetroni